As AnxA1 has been increasingly targeted as a potential predictor of IBD progression and treatment-induced remission, this evidence is of value for future clinical trials investigating PPARγ ligands for treatment of IBDs, as biomarkers which might indicate more accurately how therapeutic success on patients is more likely to be achieved, such as AnxA1, can be more thoroughly assessed. Here, PPARG is linked to inflammatory bowel disease.